3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Suspended
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Breast Neoplasms
8
Ovarian Neoplasms
6
Neoplasm Metastasis
4
Advanced Solid Tumors
4
Triple Negative Breast Neoplasms
3
Small Cell Lung Carcinoma
3
Prostatic Neoplasms
3
Leukemia, Myeloid, Acute
3
Fallopian Tube Neoplasms
3
Pancreatic Neoplasms
2
Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Triple Negative Metastatic Breast Cancer
1
Thrombocythemia, Essential
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumor
1
Sarcoma, Ewing
1
Primary Myelofibrosis
1
Polycythemia Vera
1
Neuroendocrine Tumors
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Metastatic Castration Resistant Prostate Cancer (mCRPC)
1
Mesothelioma
1
Lymphoma, Mantle-Cell
1
Lung Neoplasms
1
Interventions
talazoparib
1
olaparib
1
CX 5461
1
BAY 2315497
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Metastatic Castration Resistant Prostate Cancer (mCRPC)
×
talazoparib
×
Clear all
NCT05425862
2023-12-11
REPAIR
Peter MacCallum Cancer Centre, Australia
Phase 1
Suspended
48 enrolled